Legal status · Australia
Is Mitoglitazone legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Mitoglitazone is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Mitoglitazone in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 4 of 8 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Mitoglitazone profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
Mitoglitazone is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Mitoglitazone is
Extended male mouse median lifespan by 8.7 percent when started at 7 months, then failed a retest started at 18 months where it shortened female lifespan. In people it has completed a 356-patient phase 2b in type 2 diabetes and a 29-patient phase 2 in Alzheimer disease, both sponsor-run, neither followed by a phase 3.
Mitoglitazone is a thiazolidinedione designed to keep the insulin-sensitising effect of pioglitazone while largely avoiding the PPAR-gamma activation blamed for that class's fluid retention and weight gain. Its developer, Metabolic Solutions Development Company, traced the PPAR-gamma-independent action to a mitochondrial target it called mTOT, later identified as the mitochondrial pyruvate carrier (MPC1 and MPC2).
Mechanism: Mitoglitazone binds the mitochondrial pyruvate carrier complex (MPC1 and MPC2), identified by photo-crosslinking proteomics as the mitochondrial target of thiazolidinediones, and has minimal affinity for PPAR-gamma. Restricting pyruvate entry into mitochondria shifts fuel use and, in the developer's model, produces insulin sensitisation without the PPAR-gamma-driven fluid retention and adipose expansion.
Regulatory history: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Mitoglitazone at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Mitoglitazone in other countries
Frequently asked questions
Is Mitoglitazone legal in Australia?
No. Mitoglitazone is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy Mitoglitazone in Australia?
No approved product exists to buy. In Australia Mitoglitazone is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Mitoglitazone TGA approved?
No. In Australia Mitoglitazone is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Investigational, not approved. Completed phase 2 in type 2 diabetes (2011) and Alzheimer disease (2013) with results posted; no phase 3 registered. The lifespan extension is in male mice started at 7 months; the retest started at 18 months found no male benefit and shorter female lifespan.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Mitoglitazone live on its compound profile.
Mitoglitazone profileThis page is general information about the regulatory status of Mitoglitazone in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.